ImmersiveTouch has received the US Food and Drug Administration (FDA) 510(k) approval for ImmersiveAR, its augmented reality (AR) technology platform for use in the operating room.
The Chicago-based digital surgery company intends to start commercialising its FDA-approved AR platform in the US immediately.
ImmersiveAR builds on the company’s suite of AI-powered virtual surgical planning products and services, which reduce traditional pre-operative planning from seven days to a few minutes.
The AR platform allows surgeons to simulate surgical changes to bones and plan the final aesthetic result, customising the procedure according to the patient’s anatomy.
Also, it is accretive for hospitals to generate additional reimbursement from payors and reduce their healthcare costs, said the digital surgery company.
ImmersiveTouch CEO Jay Banerjee said: “ImmersiveAR brings a new frontier in intraoperative 3D visualisation.
“The surgical field has long relied on traditional two-dimensional imaging technology to navigate complex patient anatomy. Our platform introduces advanced holographic visualisation to transform how surgeons plan and perform procedures.”
According to the company, ImmersiveAR is designed to help surgeons visualise and interact with 3D virtual surgical plans, overlaid in an operating room environment.
It offers a fully integrated workflow, from surgical planning to intraoperative 3D visualisation.
The platform can be used in different surgical procedures and allows surgeons to double-check their planned movements and reduce the need for intraoperative trial and error.
Northwell Health Dental Medicine senior vice president David Hirsch said: “This virtual reality and augmented reality imaging provides remarkably detailed images of a patient’s anatomy, helping us foresee complications and reduce both planning and surgical time, resulting in a safer patient experience with fewer complications.”
